People with diabetes who take a class of drugs known as sodium–glucose cotransporter 2 (SGLT2) inhibitors will now need to weigh benefits against…
Tag: Invokana
The FDA issued a safety communication alerting the public about interim safety results from an ongoing clinical trial that found an increase…
A U.S. FDA safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors (such as Invokana, Farxiga and Jardiance) about the risks of too much acid in the blood and of serious urinary tract infections. Both conditions can result in hospitalization.
Several months ago the FDA warned that SGLT2 inhibitors like Invokana may cause diabetic ketoacidosis, a condition that occurs when there is…
“The bottom line with this drug is that it controlled blood sugar levels without causing weight gain and caused almost no hypoglycemia. This drug could be the backbone of new treatments for type 2 diabetes.”
The FDA has approved Janssen Pharmaceutical's new type 2 diabetes treatment, Invokana (canagliflozin). Invokana is the first in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors to be approved in the United States.